In general, among other things, compounds of Formula I are provided:
in which R
11
is e.g., 4-(pyrrolidin-1-yl)piperidin-1-yl, N-methyl-3-(pyrrolidin-1-yl)propan-1-amino, N
1
,N
1
,N
3
-trimethylpropane-1,3-diamino, N,N-dimethylpiperidin-4-amino, 3-(pyrrolidin-1-ylmethyl)azetidin-1-yl, 3-(pyrrolidin-1-ylmethanon)azetidin-1-yl, or 3-(morpholin-1-ylmethyl)azetidin-1-yl; R
13
is, e.g., phenyl optionally substituted with one or more substituents; and R
12
and R
14
are each independently hydrogen or alkyl. Methods of treatment are also provided.
In general, among other things, compounds of Formula I are provided:
in which R
11
is selected from the group consisting of benzylamino, N-methylbenzylamino, morpholino, thiomorpholino, pyrrolidino, etc.; R
13
is selected from the group consisting of 3-(1-ethanol-2-yl)phenyl, 3-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, 2-(1-ol-2,2,2-trifluoroethan-2-yl)phenyl, etc.; and R
12
and R
14
are each independently hydrogen or alkyl. Methods of treatment are also provided.